SPOTLIGHT -
Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.
Keratoconus in a pediatric population has higher prevalence than expected
ROP: Treating and preventing blindness in preterm babies
Partners collaborate on integration of AI-supported ROP telemedicine globally
Managing a changing landscape of IRD pediatric cases
An approach to preventing progression of pediatric myopia
AAO 2023: Phase III CHAMP and more trials pioneering myopia management in children